Skip to main content
Atezolizumab doubles survival of NSCLC patients with poor performance status
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Atezolizumab doubles survival of NSCLC patients with poor performance status
User login
Username
Password
Reset your password
Concept
Lead
score
Lung Cancer
1
1
Chemotherapy
0
0.82
Biologic Therapy
0
0.39
Platinum
0
0.37
Head and Neck Cancer
0
0.32
Hepatocellular Carcinoma
0
0.29
Metastasis
0
0.27
Liver Metastases
0
0.24
Brain Metastasis
0
0.22
Cancer
0
0.18
Immunotherapy
0
0.18
Small Cell Lung Cancer
0
0.18
Targeted Cancer Therapy
0
0.17
Healthcare and Medical Technology
0
0.15
Clinical Research
0
0.14
Brain
0
0.09
Concerns of Elderly
0
0.09
Geriatrics
0
0.09
Histology
0
0.09
Intravenous
0
0.09
Lung
0
0.09
Tobacco Cessation
0
0.09
Chest Pain
0
0.08
Quality of Life
0
0.08
Tobacco Use
0
0.08
Angina Pectoris
0
0.07
Biomarker
0
0.05
Europe
0
0.05
Grant
0
0.05
Hospital
0
0.05
Liver
0
0.05
Pain
0
0.05
Pain Management
0
0.05
Thorax
0
0.05
Tumor
0
0.05
Specialty
Lead
score
Hematology-Oncology
1
1
Pharmacist
0
1
Internal Medicine
0
0.43
Pulmonary Medicine
0
0.38
Neurology & Neurosurgery
0
0.35
Allergy & Clinical Immunology
0
0.34
Gastroenterology
0
0.34
Hospital Medicine
0
0.15
Pathology & Lab Medicine
0
0.13
Cardiology
0
0.07
Edit Tags